Subscribe to Search results

The Skipton Appeals Panel would not hear from affected individuals personally.

Published on:

To qualify for Skipton Fund payments a person had to have been alive from 1 April 2016 and not be eligible for a Stage 2 payment. Scotland also provided for a Stage 2 payment of £50,000 to be made to a person coinfected with HIV if they had not already received a Stage 2 payment. England and Wales provided a bereavement payment of £10,000 if a contributory factor to the person's death was Hepatitis C (or HIV if coinfected).

Published on:

The definition of when a Stage 2 payment should be given was amended to include the infected person developing B-cell non-Hodgkin's Lymphoma where that had arisen after the person contracted Hepatitis C.

Published on:

The Scottish Haemophilia Forum argued in March 2005 that: "The Skipton Fund arose only as the result of the campaigning in Scotland by the Scottish Haemophilia Forum, the Motion supported by 80 MSPs from all parties, the unanimous support of the 1999-2003 Health Committee of the Scottish Parliament and the decision of the then Health Minister Malcolm Chisholm."

Published on:

Dr Reid was advised by the civil servant who had principal responsibility at the time for blood and blood policy, Richard Gutowski, that financial assistance for people infected with Hepatitis C through blood or blood products was not justified,

Published on:

Fibrosis is a state of scarring and scarring is not flexible. A cirrhosed liver is stiff, whereas a normal liver is pliable and soft. When fibroscans became available, which measured the degree of stiffness in a liver, they were therefore also useful diagnostically. A fibroscan produced a numerical value.

Published on:

A consequence of the court's ruling in "A and Others v National Blood Authority" was that the Scottish Executive began "considering constructively the implications" of it.

Published on:

The Scottish Executive instructed NHS Scotland to enter into discussions in Scotland with Scottish litigants who had been in the same position as those in England and Wales, with a view to settling their actions under the Consumer Protection Act.

Published on:

Susan Deacon was informed that the BBC were planning to run a story on claims for compensation from haemophiliacs who had contracted Hepatitis C as a result of receiving infected blood clotting agents from the Scottish National Blood Transfusion Service in the late 1980s / early 1990s.

Published on:

Nicholas Fish began working for the Skipton Fund in November 2004 as a temp. He was the assistant to the then administrator, helping to write letters, gather evidence, answer emails and carry out general administrative duties.

Published on:

When the first administrator at Skipton was found to be defrauding the fund in 2006, the need for some continuity meant that Nicholas Fish succeeded to the job. The systems he operated were those he inherited, and had experience of applying.

Published on:

Nicholas Fish at the Skipton Fund sought advice from Elizabeth Boyd and her contacts at the Royal Free Hospital as to medical issues including whether cirrhosis was present.

Published on:

With regard to payments by the Skipton Fund, no distinction was made, save as between Stage 1 and Stage 2, between those more seriously affected physiologically, nor any account taken in the scheme itself as to the presence or degree of psychological distress, social or financial disadvantage that resulted.

Published on:

In his written evidence, Lord Hunt described his meetings with the Haemophilia Society, other groups, patients and their families as "troubling and vividly brought home to me their suffering and the need to help them as much as possible. I looked for ways to do that, but it is a matter of great regret that it took so long for successive Governments to achieve this."

Published on:

In his written evidence, Mark Mildred (chair of the Skipton Fund Appeals Panel) noted in relation to intravenous drug use: "More extensive disclosure and oral evidence tested by cross-examination might have given a more detailed picture and a better informed basis for the assessment of credibility but these were not open to us."

Published on:

The Skipton Fund Appeals Panel consisted of five members: a legal professional, three medical members (GP, haematologist and hepatologist) and a lay member.

Published on:

The Skipton Fund Appeals Panel was chaired by Mark Mildred who was an experienced solicitor who had previously been involved in the litigation brought by people with haemophilia who had contracted HIV, and had informally advised the claimants' legal teams in litigation concerning Hepatitis C and variant Creutzfeldt-Jakob disease.

Published on:

The parameters of the Skipton Fund as then proposed were confirmed in a full submission to the Secretary of State on 6 January 2004 and announced on 23 January 2004.

Published on:

An internal brief for a meeting with the chairs of the Macfarlane Trust, Eileen Trust and Skipton Fund anticipated criticisms of the Department's calculation of the current £6,400 pa average payment per recipient which was not accepted by all stakeholders.

Published on:

Anne Milton met with Christopher FitzGerald and Peter Stevens to hear new evidence in respect of the payment schemes as she considered how to respond to the Judicial Review Judgement of the previous Government's response to Lord Archer's recommendation 6(h) about the parity of payments with Ireland.

Published on: